AutoVRse, an emerging player in the industrial AI transformation sector, has successfully secured $2.4 million in funding, co-led by Singularity AMC and existing investor Lumikai. This funding aims to enhance AI-driven training solutions for the pharmaceutical and MedTech industries.
AutoVRse specializes in VR-based training and smart-glasses technology, catering to over 500,000 users across more than 50 enterprise clients globally, including major pharmaceutical companies and medical device manufacturers. The company’s unique approach involves collaborating with subject matter experts (SMEs) to capture and structure their knowledge, which is essential for compliance in regulated environments. This method ensures that the AI systems they develop are grounded in verified expertise rather than generalized data.
The company’s VRseBuilder platform transforms fragmented operational knowledge into a cohesive, machine-readable format, making it accessible to technicians and engineers in real-time. This capability is particularly vital in industries where adherence to Good Manufacturing Practices (GMP) and Quality System Regulations (QSR) is mandatory, as it allows for accurate training and procedural guidance without the risk of errors associated with generic training methods.
As the demand for standardized training solutions grows, AutoVRse is positioned to capitalize on this trend. The recent funding will support compliance certifications and enhance integrations with existing customer systems, while also expanding its market presence in North America and beyond. With its innovative solutions, AutoVRse is set to redefine workforce training in the life sciences sector, bridging the gap between expert knowledge and operational execution.